February 25, 2020
What is the value of advanced medicine for a patient living with migraine? It’s not a simple question.
December 19, 2019
Before closing the door on 2019, IfPA looks back at the trends that impacted patient access this year.
December 3, 2019
The QALY gives a one-size-fits-all measure of value that doesn’t reflect the needs and experiences of real patients.
November 12, 2019
If you don’t know ICER, you should. IfPA’s new videos explain what the health economic organization is leaving out of…
October 22, 2019
Not only is cystic fibrosis a devastating disease, most patients living with cystic fibrosis do not have access to an…
September 10, 2019
ICER recently released an updated draft of its framework. What do these changes mean for real patients who want to access innovative medicine?
June 7, 2019
Elated. Nervous. Hopeful. That’s how thousands of cystic fibrosis patients felt upon hearing last week’s news: the Food and Drug Administration will soon review a new triple combination therapy that could drastically improve their quality of life.
June 5, 2019
The Institute for Clinical and Economic Review is dashing patients’ hopes yet again.
August 9, 2018
An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.
June 8, 2018
Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report. The drugs can “substantially improve patient health outcomes,” the group concedes, but their prices exceed ICER’s cost-effectiveness threshold. One manufacturer has called ICER’s analysis “a sham.”